GIP and type 2 diabetes mellitus: The median age for patients using a GLP‐1 or GIP/GLP‐1 agonist for weight management was 38 years (IQR 29–48.5 years) compared with 69.5 years (IQR 36.75–76.75 years) using a GLP‐1 or GIP/GLP‐1 agonist for T2DM, p = 0.06.